Response to crizotinib in a squamous cell lung carcinoma patient harbouring echinoderm microtubule-associated protein-like 4-anaplastic lymphoma translocation: A case report
作者： Wenxian Wang , Zhengbo Song , Yiping Zhang
关键词:
摘要: Squamous cell lung cancer (SCC) presenting with anaplastic lymphoma kinase (ALK) translocation is rare. We present a case of ALK gene translocation-SCC in which remarkable tumor response to crizotinib was achieved after the failure prior chemoradiotherapy. Considering this response, we conclude that testing female non-smokers or any patient unresponsive initial regimen chemotherapy, recommended for SCC patients.
sci-hub.se 参考文章(12)
She-Juan An, Zhi-Hong Chen, Jian Su, Xu-Chao Zhang, Wen-Zhao Zhong, Jin-Ji Yang, Qing Zhou, Xue-Ning Yang, Ling Huang, Ji-Lin Guan, Qiang Nie, Hong-Hong Yan, Tony S. Mok, Yi-Long Wu, Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking Status PLoS ONE. ,vol. 7, pp. e40109- ,(2012) , 10.1371/JOURNAL.PONE.0040109
Jamie E. Chaft, Natasha Rekhtman, Marc Ladanyi, Gregory J. Riely, ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. Journal of Thoracic Oncology. ,vol. 7, pp. 768- 769 ,(2012) , 10.1097/JTO.0B013E31824C9485
Neal I. Lindeman, Philip T. Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Dacic, Giuseppe Giaccone, Robert Brian Jenkins, David J. Kwiatkowski, Juan-Sebastian Saldivar, Jeremy Squire, Erik Thunnissen, Marc Ladanyi, Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology Journal of Thoracic Oncology. ,vol. 8, pp. 823- 859 ,(2013) , 10.1097/JTO.0B013E318290868F
Hyojin Kim, Eunhyang Park, Yu Jung Kim, Jin-Haeng Chung, ALK rearrangement in a pure squamous cell carcinoma: the challenge of detection of ALK rearrangement Virchows Archiv. ,vol. 462, pp. 597- 599 ,(2013) , 10.1007/S00428-013-1413-5
Konstantin H. Dragnev, Gerald Gehr, Vincent A. Memoli, Laura J. Tafe, ALK-Rearranged Adenosquamous Lung Cancer Presenting as Squamous Cell Carcinoma: A Potential Challenge to Histologic Type Triaging of NSCLC Biopsies for Molecular Studies Clinical Lung Cancer. ,vol. 15, pp. e37- e40 ,(2014) , 10.1016/J.CLLC.2014.01.003
Qiushi Wang, Yong He, Xin Yang, Yubo Wang, Hualiang Xiao, Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy. BMC Pulmonary Medicine. ,vol. 14, pp. 83- 83 ,(2014) , 10.1186/1471-2466-14-83
Pablo Perez-Moreno, Elisabeth Brambilla, Roman Thomas, Jean-Charles Soria, Squamous-cell carcinoma of the lung: molecular subtypes and therapeutic opportunities Clinical Cancer Research. ,vol. 18, pp. 2443- 2451 ,(2012) , 10.1158/1078-0432.CCR-11-2370
Beow Y Yeap, Benjamin J Solomon, Gregory J Riely, Justin Gainor, Jeffrey A Engelman, Geoffrey I Shapiro, Daniel B Costa, Sai-Hong I Ou, Mohit Butaney, Ravi Salgia, Robert G Maki, Marileila Varella-Garcia, Robert C Doebele, Yung-Jue Bang, Kimary Kulig, Paulina Selaru, Yiyun Tang, Keith D Wilner, Eunice L Kwak, Jeffrey W Clark, A John Iafrate, D Ross Camidge, Alice T Shaw, Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncology. ,vol. 12, pp. 1004- 1012 ,(2011) , 10.1016/S1470-2045(11)70232-7
Rebecca Siegel, Jiemin Ma, Zhaohui Zou, Ahmedin Jemal, Cancer statistics, 2014 CA: A Cancer Journal for Clinicians. ,vol. 64, pp. 9- 29 ,(2014) , 10.3322/CAAC.21208
E. L. Kwak, D. R. Camidge, J. Clark, G. I. Shapiro, R. G. Maki, M. J. Ratain, B. Solomon, Y. Bang, S. Ou, R. Salgia, Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066 Journal of Clinical Oncology. ,vol. 27, pp. 3509- 3509 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.3509